Tags : Loxo Oncology

Bayer Exercises its Exclusive WW Option to License Vitrakvi &

Shots: With the acquisition of Loxo by Eli Lilly, Bayer exercises its option and get exclusive WW rights to develop and commercialize Vitrakvi and BAY 2731954 including in the US. Loxo to receive royalties on sales of product (Ex-the US) Acc to Nov,2017 deal Bayer, and Loxo collaborated to jointly develop and commercialize larotrectinib and […]Read More

Eli Lilly to Acquire Loxo Oncology for $8B

Shots: Eli Lily acquires Loxo Oncology, in all stock transaction for $8B. Loxo to receive $235/share in cash making $8B as total deal value, including premium based on its last day closing share price value The focus of the acquisition is to utilize Loxo’s approved oncology portfolio for patients with genomically defined cancers. The acquisition […]Read More